Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention

Expert Opinion on Investigational Drugs

Volumn 20, Issue 11, 2011, Pages 1543-1554

  Sirtori, Cesare R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anacetrapib; Cholesteryl ester transfer protein; Dalcetrapib; High density lipoproteins; Off target effects; Torcetrapib

Indexed keywords

ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TORCETRAPIB;

ATHEROSCLEROSIS; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY RISK; GENETIC RISK; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; INFECTION RISK; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PROPHYLAXIS; REVIEW; SEPSIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERLIPIDEMIAS;

EID: 80053994920     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.614946     Document Type: Review

References (52)

1. Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987;327:632-4. (Pubitemid 17086900)
2. Hesler CB, Tall AR, Swenson TL, et al. Monoclonal antibodies to the Mr 74,000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma. J Biol Chem 1988;263:5020-3
3. Marcel YL, McPherson R, Hogue M, et al. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest 1990;85:10-17 (Pubitemid 20030284)
4. Franceschini G, Werba JP, Calabresi L. Drug control of reverse cholesterol transport. Pharmacol Ther 1994;61:289-324 (Pubitemid 24207702)
5. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777-88 (Pubitemid 351846853)
6. Tsai MY, Johnson C, Kao WH, et al. Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2008;200:359-67
7. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338:86-93 (Pubitemid 28042271)
8. Regieli JJ, Jukema JW, Grobbee DE, et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 2008;29:2792-9
9. Hiura Y, Shen CS, Kokubo Y, et al. Identification of genetic markers associated with high-density lipoproteincholesterol by genome-wide screening in a Japanese population: the Suita study. Circ J 2009;73(6):1119-26
10. Teslovich TM, Musunuru K, Smith AV, Edmondson AC. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13
11. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008;358:1240-9 (Pubitemid 351439225)
12. Ridker PM, Pare G, Parker AN, et al. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2009;2:26-33
13. Talmud PJ, Drenos F, Shah S, et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet 2009;85(5):628-42
14. Zeller M, Masson D, Farnier M, et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 2007;50:1948-55 (Pubitemid 350046332)
15. Kappelle PJ, Perton F, Hillege HL, et al. High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: a nested case-control study. Atherosclerosis 2011;217:249-52
16. Corsetti JP, Gansevoort RT, Navis G, et al. LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP. Atherosclerosis 2011;214(2):373-6
17. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, et al. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol and possible decreased risk of ischemic heart disease. The Copenhagen City Heart Study. Circulation 2001;101:2197-203
18. Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006;91:3382-8 (Pubitemid 44402108)
19. Vasan RS, Pencina MJ, Robins SJ, et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009;120:2414-20
20. Ritsch A, Scharnagl H, Eller P, et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010;121:366-74
21. Duwensee K, Breitling LP, Tancevski I, et al. Cholesteryl ester transfer protein in patients with coronary heart disease. Eur J Clin Invest 2010;40:616-22
22. Sanders AE, Wang C, Katz M, et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA 2010;303:150-8
23. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7 (Pubitemid 30469005)
24. Huang Z, Inazu A, Nohara A, et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 2002;103:587-94 (Pubitemid 36005711)
25. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005;25:1057-64 (Pubitemid 40627855)
26. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006;47:537-52 (Pubitemid 43345595)
27. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22 (Pubitemid 350146106)
28. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008;154:1465-73
29. Cazita PM, Barbeiro DF, Moretti AI, et al. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock 2008;30:590-5
30. Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010;51:2739-52
31. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transpor. J Lipid Res 2010;51:3443-5432.
32. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14 (Pubitemid 350192656)
33. Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010;31:480-8
34. Miyares MA. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Ann Pharmacother 2011;45:84-94
35. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65 (Pubitemid 34517159)
36. Derks M, Abt M, Phelan M, et al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 2010;50:1188-201
37. Krishna R, Garg A, Panebianco D, et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2009;68:535-45
38. Derks M, Anzures-Cabrera J, Turnbull L, Phelan M. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study. Clin Drug Investig 2011;31:325-35
39. Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007;27:1132-8 (Pubitemid 46641969)
40. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010;30:1430-8
41. Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008;84:679-83
42. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352-60
43. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
44. Clark RW, Cunningham D, Cong Y, et al. Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection. J Lipid Res 2010;51:967-74
45. Joy T, Hegele RA. The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol 2009;24:364-71
46. Franceschini G, Sirtori M, Vaccarino V, et al. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 1989;9:462-9 (Pubitemid 19184480)
47. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337(6):365-72 (Pubitemid 27328366)
48. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-16 (Pubitemid 34158156)
49. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis 2009;207:16-23
50. Miyauchi K, et al. Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis 2011; In press
51. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008;118:2506-14
52. Brown BG. Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression. Circulation 2006;113:1382-4 (Pubitemid 43739433)